Prolastin United States
United States  |   For US Healthcare Professionals Only

 Advanced Search
Print This Page
Patients and Consumers

Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified)

Immune globulin intravenous, sometimes referred to as "IGIV" or "IVIG," is also known as pooled human gamma globulin or, simply, gamma globulin. IGIV belongs to a group of medicines that work by affecting a patient's immune system. For decades IGIV has been used to treat a variety of infectious or inflammatory diseases, as well as for the treatment of a variety of autoimmune disorders. A doctor prescribes IGIV therapy.

Please note: Country-specific regulatory requirements limit the information we can provide about our products. In addition, approved indications (uses), product labels, and packaging for a prescription drug may differ between countries. Please refer to the prescribing information provided for your country of residence.

Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) reaches patients around the world, including in:

Canada

Europe

USA

Residents of other countries can learn about Talecris' immunology products on the Talecris International Web site.

Or, find local distributors by selecting your region on the location map.


Important Safety Information

Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please click here for Prolastin® full Prescribing Information.

Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.


Prolastin® Home  |   About Prolastin®  |   Understanding Alpha1-Antitrypsin Deficiency  |   Alpha1-Antitrypsin Deficiency Diagnosis & Treatment
Prolastin® Clinical Data  |   Prolastin DirectSM  |   Tools & Resources  |   Prescribing Information  |   For Patients and Consumers  |   Site Map



 
  Talecris Biotherapeutics   Contact Talecris    General Conditions of Use    Privacy Statement    Contact Prolastin®
 
This site is intended for US residents only. Non-US residents can go to www.Talecris.com.
© 2007 Talecris Biotherapeutics, Inc.